AIRLINK 172.19 Decreased By ▼ -0.96 (-0.55%)
BOP 10.59 Decreased By ▼ -0.06 (-0.56%)
CNERGY 8.47 Decreased By ▼ -0.05 (-0.59%)
CPHL 100.30 Increased By ▲ 2.84 (2.91%)
FCCL 46.59 Decreased By ▼ -0.66 (-1.4%)
FFL 15.43 Increased By ▲ 0.01 (0.06%)
FLYNG 27.49 Decreased By ▼ -0.64 (-2.28%)
HUBC 138.80 Decreased By ▼ -0.11 (-0.08%)
HUMNL 12.85 Increased By ▲ 0.04 (0.31%)
KEL 4.47 Decreased By ▼ -0.07 (-1.54%)
KOSM 5.50 Decreased By ▼ -0.05 (-0.9%)
MLCF 61.88 Decreased By ▼ -0.38 (-0.61%)
OGDC 214.00 Decreased By ▼ -0.75 (-0.35%)
PACE 5.48 Decreased By ▼ -0.07 (-1.26%)
PAEL 46.20 Increased By ▲ 1.34 (2.99%)
PIAHCLA 19.01 Increased By ▲ 0.31 (1.66%)
PIBTL 10.62 Decreased By ▼ -0.12 (-1.12%)
POWER 12.52 Increased By ▲ 0.26 (2.12%)
PPL 172.85 Decreased By ▼ -1.02 (-0.59%)
PRL 36.30 Increased By ▲ 0.08 (0.22%)
PTC 23.50 Decreased By ▼ -0.06 (-0.25%)
SEARL 97.75 Increased By ▲ 2.44 (2.56%)
SSGC 40.65 Increased By ▲ 1.52 (3.88%)
SYM 13.90 Decreased By ▼ -0.12 (-0.86%)
TELE 7.20 Decreased By ▼ -0.03 (-0.41%)
TPLP 10.16 Decreased By ▼ -0.13 (-1.26%)
TRG 64.11 Decreased By ▼ -0.57 (-0.88%)
WAVESAPP 10.03 Decreased By ▼ -0.01 (-0.1%)
WTL 1.31 Decreased By ▼ -0.02 (-1.5%)
YOUW 3.70 No Change ▼ 0.00 (0%)
BR100 12,427 Decreased By -64.9 (-0.52%)
BR30 37,605 Decreased By -89.3 (-0.24%)
KSE100 115,805 Decreased By -384.4 (-0.33%)
KSE30 35,581 Decreased By -169.4 (-0.47%)

French drugmaker Sanofi reported a fourth-quarter profit that came in-line with analysts’ estimates on Thursday, and said it would buy back 5 billion euros ($5.21 billion) in shares this year as it seeks to build investor confidence in its drug pipeline.

Sanofi, one of the world’s largest maker of vaccines and a leader in anti-inflammatory drugs, also said it expects sales to grow by a mid-to-high single-digit percentage in 2025, at a time the company transitions into a pure-play drugmaker.

Sanofi is close to selling a 50% stake in its consumer health business Opella to investor Clayton Dubilier & Rice, and said it expects the deal to close in the second quarter at the earliest.

Quarterly business operating income, excluding one-off items, fell by 7.7% to 2.08 billion euros but met the average analyst estimate in a poll posted on the company’s website.

Sales of its blockbuster asthma drug Dupixent rose 16% to 3.46 billion euros, compared to 3.61 billion euros expected on average by analysts in a company-provided poll.

The company said sales growth had been hit by fewer business days in the quarter compared to prior periods.

Investor expectations have been high for the anti-inflammatory drug, on which Sanofi partners with Regeneron , after it gained approval for a common lung condition called chronic obstructive pulmonary disease in September.

Sanofi profit slips on generic competition and currency effects

Sales of Beyfortus, a new treatment to protect newborns from a common respiratory virus, more than doubled to 841 million euros, beating estimates of 648 million euros.

Vaccines sales rose a currency-adjusted 10.8% to 2.18 billion euros in the quarter, ahead of a 1.91 billion euro analyst consensus.

Comments

200 characters